Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733145 · ClinicalTrials.gov registry record · Phase 4
Angiotensin II in General Anesthesia
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT03733145 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 32 participants.
The verdict
NCT03733145, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.
Interventions
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-10-03 |
| Est. Completion | 2023-03-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733145
The ClinicalTrials.gov registry entry for NCT03733145 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiotensin II is the first listed.
NCT03733145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733145 about?
NCT03733145 is a clinical study titled "Angiotensin II in General Anesthesia". Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzy...
What is the current status of trial NCT03733145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2019-10-03. Estimated completion is 2023-03-21.
What interventions are being tested in trial NCT03733145?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT03733145?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.